Description
TYPBAR TCV is the world’s first clinically proven Typhoid Conjugate Vaccine, providing long-lasting protection against Salmonella Typhi. Manufactured by Bharat Biotech, it represents a breakthrough in immunization technology by linking the Vi polysaccharide antigen to a carrier protein (tetanus toxoid). Unlike older typhoid vaccines, Typbar TCV induces a stronger, more durable immune response and is the only typhoid vaccine approved for use in infants as young as 6 months. It is an essential preventive measure for travelers, children, and individuals living in or visiting areas where typhoid fever is endemic.
